Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. - Jones,S.E.; Seynaeve,C.; Hasenburg,A. (Cancer Res, 2009)